Published Date: 28-Jul-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Inhalation Anesthesia Market size is expected to reach $1.9 billion by 2028, rising at a market growth of 8.7% CAGR during the forecast period.
The Sevoflurane segment acquired maximum revenue share in the Global Inhalation Anesthesia Market by Drug in 2021, thereby, achieving a market value of $889.6 Million by 2028. It is due to the reason that it is potent, quick-acting, and has a faster emergence and recovery than other medications on the market; yet, it is more expensive than its competitors. As a result of these factors, surgeons prefer sevoflurane for induction and maintenance of anesthesia during surgical procedures.
The Induction segment is showcasing a CAGR of 11.2% during (2022 - 2028). A drug's therapeutic index, Minimum Alveolar Concentration (MAC), potency, patient's age, rate of metabolism by kidney/liver, compatibility with other medicines, and blood/gas solubility are all factors that influence anesthesia induction. Inhalation general anesthetics work in the central nervous system in a variety of ways, depending on blood and gas solubility, as well as the drug's Minimum Alveolar Concentration (MAC) concentration.
The North America market dominated the Global Inhalation Anesthesia Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $673.9 Million by 2028. The Asia Pacific market is estimated to witness a CAGR of 9.5% during (2022 - 2028). Additionally, The Europe market would experience a CAGR of 8.5% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Novartis AG, Piramal Enterprises Limited, Hikma Pharmaceuticals PLC, Fresenius SE & Co. KGaA, Baxter International, Inc., AbbVie, Inc., Halocarbon Products Corporation, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lunan Pharmaceutical Group Co., Ltd., and Troikaa Pharmaceuticals Limited.
Unique Offerings from KBV Research